Randomized trial · people

Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with MASH and stage F2 or F3 fibrosis, liver fat and non-invasive liver markers kept improving on pemvidutide through 48 weeks, with nausea more common in the higher-dose arm.

Kind
Randomized trial
Studied in
People
Number studied
212
Published
2026
Journal
Lancet Gastroenterol Hepatol

What they tested

The team tested whether 48 weeks of weekly pemvidutide improves liver fat, liver inflammation and liver scarring markers in people with MASH (metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation) compared with placebo.

How the study was done

In this randomized, double-blind, placebo-controlled phase 2b trial, 212 people with biopsy-confirmed MASH and stage F2 or F3 fibrosis (liver scarring) were assigned to pemvidutide 1.2 mg, pemvidutide 1.8 mg or placebo (a dummy shot), each given once a week under the skin. Treatment lasted 48 weeks and started at the full dose, and patients were enrolled from 83 hospitals and research clinics across two countries, the USA and Australia.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 48, liver fat fell by 45.2% in the 1.2 mg arm and 54.7% in the 1.8 mg arm, versus 8.2% on placebo. Corrected T1 relaxation time, an imaging measure, dropped by 124.2 ms and 139.5 ms on pemvidutide versus 20.5 ms on placebo, and ALT, a liver enzyme in the blood, fell by 37.8 and 37.4 IU/L versus 10.3 IU/L on placebo. The enhanced liver fibrosis score fell by 0.49 and 0.58 on pemvidutide but rose by 0.16 on placebo. Nausea was the most common side effect, in 22% of the 1.2 mg arm, 41% of the 1.8 mg arm and 17% of the placebo arm, and no severe or serious side effects were judged to be caused by the drug.

What it doesn’t show

No liver biopsies were taken at week 48, so these results rest on non-invasive tests and are secondary endpoints, not the trial's main biopsy-based goals, which were measured at week 24. It was a mid-size phase 2b trial funded by Altimmune.

The paper

Noureddin et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet Gastroenterol Hepatol. 2026.

The compound

More studies on Pemvidutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo